DOCSLIB.ORG

Energy Efficiency & Sustainability

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Energy Efficiency & Sustainability Energy Efficiency & Sustainability Simon Garrett EHS2 Manager, Janssen Cork EHS2 Comprehensive Care Group MD&D Surgical Care Group Pharmaceuticals Consumer Janssen Supply Chain Overview Janssen Supply Chain Ireland J&J - The Structure Our Credo Healthy Future 2015 Sustainability Global mpanies… In Co 5 g in 7 at r C e Co o p unt u O 5 ri es n 7 t r 1 i in e s s 0 t a c r u o d u 5 o n r d p t 2 g h n i e l l W e S o r l d . Collaboration & Connectivity People - Applications - Infrastructure Supply Chain Worldwide Comprehensive Care Group MD&D Pharmaceuticals Consumer Surgical Care Group Janssen Supply Chain Janssen Supply Chain Ireland T C E N N S O H C A PE D LIVE OUR our credo EL CREDO IV E R D A E Customers L We believe our first responsibility is to the doctors, nurses and patients, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality. We must constantly strive to reduce our costs in order to maintain reasonable prices. Customers’ orders must be serviced promptly and accurately. Our suppliers and distributors must have an opportunity to make a fair profit. We are responsible to our employees, the men and women who work with us throughout Employees the world. Everyone must be considered as an individual. We must respect their dignity and recognize their merit. They must have a sense of security in their jobs. Compensation must be fair and adequate, and working conditions clean, orderly and safe. We must be mindful of ways to help our employees fulfil their family responsibilities. Employees must feel free to make suggestions and complaints. There must be equal opportunity for employment, development and advancement for those qualified. We must provide competent management, and their actions must be just and ethical. Communities We are responsible to the communities in which we live and work and to the world community as well. We must be good citizens - support good works and charities and bear our fair share of taxes. Robert Wood Johnson We must encourage civic improvements and better health and education. We must maintain in good order the property we are privileged to use, protecting the environment and natural resources Stockholders Our final responsibility is to our stockholders. Business must make a sound profit. We must experiment with new ideas. Research must be carried on, innovative programs developed and mistakes paid for. New equipment must be purchased, new facilities provided and new products launched. Reserves must be created to provide for adverse times. When we operate according to these principles, the stockholders should realize a fair return. 93% of CEOs said that sustainability issues were crucial to the success of their business At Johnson & Johnson, we believe human health benefits from a healthy planet. Making our products more sustainable through design magnifies their benefits and is simply good business. - Former CEO William Weldon, on sustainability Sustainability Fosters Employee Recruitment and Retention Companies with strong sustainability programs have: 55% better morale 43% more efficient business processes 43% stronger public image 38% better employee loyalty Source: Society for Human Resources Management study 2012 Sustainability is Rooted in Our Heritage Fulfilling our Credo responsibilities so people, planet & business can all live in good health today & tomorrow. Healthy People Healthy Planet Healthy Business • Research and development for • Building on our legacy in • Enhancing outcome neglected diseases safeguarding the planet measurement in philanthropy • Affordable access to medicines • Reduce the environmental impact • Partnering with suppliers that • Advancing community wellness of our operations embrace sustainability • Fostering the most engaged, • Increase the sustainable design • Committing to enhanced health-conscious and safe of our products transparency and accessing the employees in the world power of external collaboration Healthy Future 2015 Goals Healthy Future 2015—which launched January 1, 2011—is our five-year citizenship and sustainability strategy. This table provides an overview of the seven strategic priorities we established. Advancing Global Health • Build research partnerships to develop treatments for neglected diseases of the developing world • Provide affordable access to HIV and tuberculosis treatments in least-developed and middle-income countries • Pioneer business models that improve affordability of our medicines in middle-income countries • Donate our treatment for intestinal worms in countries of prevalence Safeguarding the Planet • Reduce the environmental impacts of our operations • Increase the sustainable design of our products Supplier Sustainability • Establish sustainable procurement criteria and processes to catalyze improved supplier performance and diversity • Reinforce our human rights policies, processes and education with suppliers to ensure these rights are respected in all our engagements Engaged, Health-Conscious, Safe Employees • Foster an extraordinary healthy workplace environment that supports improved employee engagement and performance • Achieve benchmark safety and health performance Advancing Community Wellness • Implement health education initiatives that increase public understanding of basic health indicators and how to effectively access health resources Philanthropy Measurement • Raise the standard of outcomes measurement in philanthropy by increasing our philanthropic partners’ capacity to measure program health-related outcomes Transparency and Collaborations • Share product sustainability information, enabling people to align their lives with their social and environmental values • Identify key stakeholders and regularly engage with them on a range of sustainability concerns and opportunities • Enhance sustainability reporting 33 Reduce Facility Impacts 2015 Goals: • 20% absolute reduction in facility CO2 emissions by 2020 • Increase onsite clean-technology energy capacity to 50 MW • 20% decrease in fleet CO2 emissions per mile • 10% absolute reduction total waste disposal & water consumption Commitment to Clean Energy Currently 38.7 MW installed or in-progress • 30 Solar • 10 Cogeneration • 3 Biomass • 2 Geothermal 4 MW PV array, 3,000kW Tri-Generation New Brunswick, NJ Limerick, Ireland Two 500 kW wood chip boilers 4 MW PV array, Cork, Ireland New Brunswick, NJ Commitment to Clean Energy Project pipeline of over 15MW • 4 Wind • 5 Solar • 3 Cogeneration Little Island Janssen Sustainability One-pager Environmental - How we Protect our Planet Packaging Facility Impact and Water Use Innovation Earthwards Renewable Energy Use Commitment to Energy Efficiency Variable speed air Lighting upgrade HCS, Heat recovery chiller Lifescan, compressor, J&J Mumbai Memphis Puerto Rico Commitment to Energy Efficiency Chiller upgrade Vistakon, Boiler upgrade Gas Conversion Jacksonville J&J UK J&J Thailand Campus Ireland T EC N SH N A O P C E Eithicon Biosurgery Vistakon Vision Care Dublin Janssen Supply Chain Limerick Janssen Research & Development Cork Johnson & Johnson (Ireland) Limited D Biologics (Ireland) E Pharmaceutical Johnson & Johnson Medical L Research & Development D IV A DePuy Synthes E E Companies of Johnson & Johnson R L Campus Ireland Janssen Biologics (Ireland), Ringaskiddy, Cork Janssen Pharmaceutical, Little Island, Cork DePuy Ireland, Ringaskiddy, Cork Vistakon, National Technology Park, Limerick Johnson & Johnson Ireland Ltd., Tallaght, Dublin Ethicon, National Technology Park, Limerick T EC N SH N A O P Local Focus C E Dublin Limerick Cork D Biologics (Ireland) E Pharmaceutical L Research & Development D I A V E ER L Campus Ireland Dublin Limerick Cork Biologics (Ireland) Pharmaceutical Research & Development T EC N SH N A O P C E Dublin Limerick Cork D Biologics (Ireland) E Pharmaceutical L Research & Development D Quarterly leadership meetings I A V E ER L Campus Ireland Resource Optimization and Knowledge Sharing Standardized Programmes and Strategies Leveraged Cost Reduction Opportunities Lean-Safe-Green Sustainable Relationships in the Value Stream T EC N SH N A O P C E Dublin Limerick Cork Leveraged Cost Savings D Biologics (Ireland) E Pharmaceutical L Research & Development D I A V E ER L Campus Ireland Health Surveillance Waste Disposal Leveraged Environmental /Auditing Cost Savings Monitoring EHS Training /Consultants Leadership & People Development – ‘Power of One’ T EC N SH N A O P C E Dublin Limerick Cork D Biologics (Ireland) Best Practice & SME Sharing Pharmaceutical E L Research & Development D I A V E ER L Good Saves Campus Ireland EHS IT Systems – EnviroManager E-Induction - Log on at www.jnjinduction.com Revenue Generating Waste Recycling PSM Training/Auditing IPPC Licence BCP Simulations Contractor Management REACH/CLP Share Point Site Sustainability @ Campus Ireland First wind turbines of any Fulfilling Our Credo responsibilities so people, planet & business can site within JnJ worldwide... all live in good health, today & tomorrow. ”iconic project for Ireland and JnJ” CONNECT SHAPE LEAD DELIVER Committing to accessing the Campus Ireland will achieve Product Stewardship Our EHS Awards power of external collaboration 50% of clean tech generation ISO14001 – Environmental Management System OHSAS 18000 – Safety management System s Collabora target set by JnJ by 2015 pu tio EN 160001 first of any business in Europe m n a ISO 50001 member site was first of jnj worldwide C Product MarMargargaret’s’s iinformationnformation Stewardship
Load more

Recommended publications
  • 2020 Health for Humanity Report
    2020 Health for Humanity Report Progress in Sustainability Contents | Message from Our CEO | Our Approach | United in Defeating COVID-19 | Better Health for All | Responsible Business Practices | Reporting Hub Contents Message from Our Chairman and CEO 3 2020 Year in Brief 4 Our Recognitions 5 Our Approach 6 Health for Humanity Strategy & Goals 9 Sustainability Governance 13 Sustainability Priorities 14 United in Defeating COVID-19 15 Caring for Patients 17 Supporting the Front Lines of Care 24 Protecting Employees 25 Supply Chain Resilience 28 Better Health for All 30 Innovation 31 Global Public Health Strategy 35 Access & Affordability 45 Strengthening Health Systems 48 Responsible Business Practices 52 Ethics & Values 53 Our People 60 Product Quality & Safety 74 Environmental Health 79 Responsible Supply Base 90 ABOVE: During the COVID-19 pandemic, Report overview community healthcare workers in Peru Reporting Hub 98 This Report details the progress of the Johnson & Johnson Family traveled door-to-door to reach children with ESG Summary 98 of Companies in sustainability. It is also our primary source of VERMOX Chewable tablets for treatment of Performance Data 98 annual disclosure on environmental, social and governance intestinal worms. The medicine is donated GRI Content Index 98 (ESG) performance and should be reviewed in conjunction by Johnson & Johnson and implemented GRI Culture of Health for Business Framework 98 with disclosures on the ESG Policies & Positions page. Data by INMED Partnerships for Children. SASB Index 98 in this Report cover the period between January 1, 2020, and Photo by INMED Partnerships for Children. TCFD 98 December 31, 2020, unless otherwise noted.
    [Show full text]
  • Business Case Study Competitive Advantage and CSR
    Business Case Johnson & Johnson Is there a connection between being socially responsible and building sustainable competitive advantage? ©2008 National Safety Council Johnson & Johnson Business Case Study Competitive Advantage and CSR BUSINESS CASE SCENARIO Perry Somers, a second-year MBA student, thoroughly enjoyed his summer internship at one of Wall Street’s top investment banks. His mentor had taught him the value of looking beyond standard financial analyses to truly understand the underlying logic that supports an organization’s decisions and their ultimate impact on the long-term success of a company. The intense research and systematic analysis required to gain unique insights appealed to the engineer in him (Perry graduated cum laude from an engineering program five years ago). Perry’s summer experience had also solidified his commitment to famed economist Milton Friedman’s claim that the social responsibility of business is to increase its profits.i While many of his classmates were off at rallies and conferences advocating for more corporate involvement in social causes, Perry stayed focused on his prime reason for attending business school: learning how to create value for shareholders. Perry was especially energized when he learned that his business school had named William Weldon, CEO of Johnson & Johnson, its Business Leader of the Year. Perry had studied the pharmaceutical industry during his internship and had a number of lingering questions. He hoped to have an opportunity to ask Mr. Weldon those questions when the CEO came to campus to receive the award and give his acceptance speech. As Perry reviewed his notes from the summer, Johnson & Johnson’s stated commitment to “socially responsible” policies and practices raised questions for him.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Caring for the World . . .One Person at a Time™ Inspires and Unites the People of Johnson & Johnson
    OUR CARING TRANSFORMS 2007 Annual Report Caring for the world . .one person at a time™ inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. The people in our more than 250 companies come to work each day inspired by their personal knowledge that their caring transforms people’s lives . one person at a time. On the following pages, we invite you to see for yourself. Our Caring Transforms ON THE COVER Johnson & Johnson is founding sponsor and continues to support Safe Kids Worldwide®. For 20 years the organization has grown, now teaching prevention as a way to save children’s lives in 17 countries around the world. In Brazil, Nayra Yara da Paz de Jesus carefully washes her hands, a safe, healthy habit she and other children are learning from a local Safe Kids® program. Find out more in our story on page 22. C H A I R M A N ’ S L E T T E R To Our Shareholders Caring for the health and well-being of people throughout the world is an extraordinary business. It is a business where people are passionate about their work, because it matters. It matters to their families, to their communities and to the world. It is a business filled with tremendous opportunity for leadership and growth in the 21st century; a business where unmet needs still abound and where people around the world WILLIAM C.
    [Show full text]
  • 2014 Annual Report • 1 Management’S Discussion and Analysis of Results of Operations and Financial Condition
    ANNUAL REPORT 2014 MARCH 2015 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer I am often asked what led me to work in Perhaps there’s no better proof of that than the THERE IS health care and why I chose to spend most success Johnson & Johnson achieved in 2014. NO COMPANY of my career at Johnson & Johnson. From my We delivered solid financial results, with full-year BETTER first job at Janssen, the flagship company of 2014 sales of $74.3 billion and adjusted net POSITIONED our Pharmaceutical segment, to my current earnings of $17.1 billion†, while also continuing TO HELP MEET role as the company’s Chairman and CEO to make investments to accelerate growth for THESE URGENT 25 years later, the answer always begins the long term. NEEDS THAN with Our Credo. JOHNSON & And while I am pleased with our performance, JOHNSON A simple yet powerful document penned we know that we can never rest, because by General Robert Wood Johnson, the son of providing sustainable high-quality health care our founder and our company’s first Chairman, is one of our society’s greatest challenges. Our Credo outlines the Company’s commitments and responsibilities to the people and This is an unprecedented era in human history. communities we touch every day with our The historic aging rate of the world’s population, products and services. For more than 70 years along with a growing middle class around the now, it has served as the moral compass of world, brings dramatically greater demand for Johnson & Johnson – ensuring we never lose higher quality health care; and governments sight of our strong values and the important and health systems must manage this with needs of the many stakeholders we serve.
    [Show full text]
  • Johnson & Johnson
    TRILLIUM ASSET MANAGEMENT January 19, 2021 Via e-mail at [email protected] Securities and Exchange Commission Office of the Chief Counsel Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Request by Johnson & Johnson to omit Proposal submitted by submitted by Trillium Asset Management (“Trillium”) on behalf of Christopher and Anne Ellinger and co-filers. Ladies and Gentlemen, This is a supplement to Trillium Asset Management LLC’s (acting on behalf Christopher and Anne Ellinger and co-filers (together, the “Proponents”)) January 6 and 10, 2021 letters and in response to Johnson & Johnson’s (“J&J”, “JNJ”, or the “Company”) December 16, 2020 and January 15, 2021 letters regarding a shareholder proposal (the "Proposal) submitted to the Company. The Proposal asks J&J to publish a third-party audit on racial impact and civil rights. 1. Johnson & Johnson has misrepresented the essential element of the Proposal. The Company asserts that “the essential objective of the Proposal is to obtain a report on ways Johnson & Johnson can improve the racial impact of its policies, practices, products and services.” That description entirely ignores the third-party audit request as the center of the Proposal. This failure to accurately and fairly describe the Proposal – effectively an effort to twist the words of the Proposal – is fatal for the Company’s argument. As is abundantly clear in a plain reading of the proposal the request is for: a third-party audit (within a reasonable time, at a reasonable cost, and excluding confidential/proprietary information) to review its corporate policies, practices, products, and services, above and beyond legal and regulatory matters; to assess the racial impact of the company's policies, practices, products and services; and to provide recommendations for improving the company’s racial impact.
    [Show full text]
  • 2002 Annual Report Three Years in Brief–Worldwide
    2002 Annual Report Three Years in Brief–Worldwide % Change (Dollars in Millions Except Per Share Figures) 2002 2001 2000 2002 2001 Sales to customers $36,298 $ 32,317 29,172 12.3 10.8 Net earnings* 6,597 5,668 4,953 16.4 14.4 Cash dividends paid 2,381 2,047 1,724 16.3 18.7 Shareholders’ equity 22,697 24,233 20,395 (6.3) 18.8 Percent return on average shareholders’ equity 28.1 25.4 26.5 – – Per Share Net earnings - basic 2.20 1.87 1.65 17.6 13.3 - diluted 2.16 1.84 1.61 17.4 14.3 Cash dividends paid 0.795 0.70 0.62 13.6 12.9 Shareholders’ equity 7.65 7.95 6.77 (3.8) 17.4 Market price (year-end close) 53.11 59.86 52.53 (11.3) 14.0 Average shares outstanding (millions) - basic 2,998.3 3,033.8 2,993.5 (1.2) 1.3 - diluted 3,054.1 3,099.3 3,099.2 (1.5) 0.0 Number of employees (thousands) 108.3 101.8 100.9 6.4 0.9 * Net earnings and earnings per share for 2002 include In-process research and development (IPR&D) charges of $189 million or .07 diluted earnings per share related to the acquisitions of Tibotec-Virco N.V. and Obtech Medical AG. Excluding the impact of these charges, 2002 net earnings increased 16.8% over 2001. Net earnings and earnings per share in 2001 and 2000 include $231 million or .07 diluted earnings per share and $45 million or .02 diluted earnings per share, respectively, related to IPR&D and ALZA merger costs in 2001 and IPR&D net of restructuring gains in 2000.
    [Show full text]
  • Johnson & Johnson
    SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 1440 NEW YORK AVENUE, N.W. WASHINGTON, D.C. 20005-2111 ________ FIRM/AFFILIATE OFFICES ----------- TEL: (202) 371-7000 BOSTON CHICAGO FAX: (202) 393-5760 HOUSTON LOS ANGELES www.skadden.com NEW YORK DIRECT DIAL PALO ALTO 202-371-7233 WILMINGTON DIRECT FAX ----------- 202-661-8280 BEIJING EMAIL ADDRESS BRUSSELS [email protected] FRANKFURT HONG KONG LONDON MOSCOW MUNICH PARIS BY EMAIL SÃO PAULO ([email protected]) SEOUL SHANGHAI SINGAPORE TOKYO TORONTO December 11, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Chief Counsel 100 F Street, N.E. Washington, D.C. 20549 RE: Johnson & Johnson – 2021 Annual Meeting Omission of Shareholder Proposal of the Remmer Family Foundation Inc (S) and the KFP CA Limited Partnership Ladies and Gentlemen: Pursuant to Rule 14a-8(j) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we are writing on behalf of our client, Johnson & Johnson, a New Jersey corporation, to request that the Staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) concur with Johnson & Johnson’s view that, for the reasons stated below, it may exclude the shareholder proposal and supporting statement (the “Proposal”) submitted by As You Sow on behalf of the Remmer Family Foundation Inc (S) (the “Foundation”), and co-filed by the KFP CA Limited Partnership (the “Partnership”), from the proxy materials to be distributed by Johnson & Johnson in connection with its 2021 annual meeting of shareholders (the “2021 proxy materials”).
    [Show full text]
  • J&J Safety, Health & Environmental Goes “Beyond
    THE ROBERT W. CAMPBELL AWARD The International Award for Business Excellence through Environmental, Health and Safety Management GLOBAL PARTNERS International Institute . of Risk and Safety Management (Worldwide) . International Safety Council . National Safety Council of Australia LTD J&J Safety, Health & Environmental . Minerva Canada . Workplace Safety & Goes “Beyond Compliance” to Create Prevention Services . China Occupational Safety and Health a Competitive Advantage Association . Institute of Safety and Health Practitioners, Hong Kong Submitted by: . Occupational Safety Johnson & Johnson and Health Council, Hong Kong SAR . Chinese Association of Workplace Safety . European Network Education and Training in Occupational Safety and Health, ENETOSH . BG RCI . National Safety Council of India . Korea Occupational Safety & Health Agency . Center of Environmental Safety and Health Technology . Taiwanese Institute of Occupational Health and Safety Attention The information contained in this material is for educational use only; it may not be modified, copied, published, disclosed, distributed, displayed or exhibited, in either electronic or printed formats without written authorization from the National Safety Council. By downloading this document you further agree to the Terms and Conditions of the Campbell Award/Campbell Institute website. DEDICATE ▪ LEAD ▪ CONTRIBUTE 1121 Spring Lake Drive ▪ Itasca, IL 60143-3201 USA ▪ [email protected] ▪ CampbellAward.org THE ROBERT W. CAMPBELL AWARD - 2005 CASE STUDY SUBMITTAL Johnson & Johnson Safety, Health & Environment Goes “Beyond Compliance” to Create a Competitive Advantage for our Global Businesses Executive Summary: Johnson & Johnson’s Safety, Health & Environmental (SH&E) functions are organized under the Technical Resources & Compliance Group (TRC) to optimally service 200 operating companies worldwide related to the manufacture of health care products for the consumer, pharmaceutical, medical devices and diagnostics markets.
    [Show full text]
  • Johnson & Johnson
    SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 1440 NEW YORK AVENUE, N.W. WASHINGTON, D.C. 20005-2111 ________ FIRM/AFFILIATE OFFICES ----------- TEL: (202) 371-7000 BOSTON CHICAGO FAX: (202) 393-5760 HOUSTON LOS ANGELES www.skadden.com NEW YORK DIRECT DIAL PALO ALTO 202-371-7233 WILMINGTON DIRECT FAX ----------- 202-661-8280 BEIJING EMAIL ADDRESS BRUSSELS [email protected] FRANKFURT HONG KONG LONDON MOSCOW MUNICH PARIS SÃO PAULO BY EMAIL ([email protected]) SEOUL SHANGHAI SINGAPORE TOKYO TORONTO December 11, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Chief Counsel 100 F Street, N.E. Washington, D.C. 20549 RE: Johnson & Johnson – 2021 Annual Meeting Omission of Shareholder Proposal of Oxfam America, Inc. and co-filers1 Ladies and Gentlemen: Pursuant to Rule 14a-8(j) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we are writing on behalf of our client, Johnson & Johnson, a New Jersey corporation, to request that the Staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) concur with Johnson & Johnson’s view that, for the reasons stated below, it may exclude the shareholder proposal and supporting statement (the “Proposal”) submitted by Oxfam America, Inc. (“Oxfam”) and co-filers from the proxy materials to be distributed by Johnson & Johnson in connection with its 2021 annual 1 The following shareholders have co-filed the Proposal: Achmea Investment Management; Benedictine Sisters of Boerne, Texas; Benedictine Sisters of Virginia, Inc.; CommonSpirit Health; Congregation of Divine Providence; Mercy Investment Services, Inc.; Monasterio De San Benito; PeaceHealth; Providence Trust; The Sisters of Charity of Saint Elizabeth; The Sisters of Providence, Mother Joseph Province; and Trinity Health.
    [Show full text]
  • SMDP Medtech 22-26 Sept
    2018 SMDP MedTech 22-26 Sept. PHILADELPHIA www.icpdprograms.org Special thanks to the SMDP MedTech Outreach Monday, September 24th: Pennovation & Planning and SMDP MedTech Selection Committees 7:30-8:15am Bus Leaves Host Hotel at 7am Saturday, September 22nd: Scholars & Mentors Breakfast Discussion: --- Hotel Check-in (SMDP Scholars) Career Goals & Action Items 6–7pm Reception: Celebration of Mentoring Mentor Debrief (SMDP Mentors 7:45-8am) & Diversity in Medical Technology 8:15-8:30am Welcome by Kate Merton, Ph.D., JLABS 7–8pm Master of Ceremonies: Todd Fonseca, 8:30-9am Mentoring Portal Orientation Vice President, Clinical Research and Speaker: Dustielyn Savage, Programs Technical Communications, Medtronic Manager, International Center for Keynote: Josh Ghaim, Ph.D., Professional Development Chief Technology Officer, Johnson 9-9:45am Getting Hired: Job Search Tools and How to Pursue Job Opportunities & Johnson Consumer Companies 8-9pm Networking & Refreshments (Tips from Human Resource Insiders) 9:45-10:15am Career Networking at Industry Events: Sunday, September 23rd: DePuy Synthes An Introduction to The MedTech Conference 7:30-8am Registration & Breakfast Facilitator: Roberto Monserrate, Director Bus Leaves Host Hotel at 6:30am Government Affairs, Amgen 8-8:15am Opening Remarks 10:15-10:30am Break Speaker: Scott May, Executive Director, 10:30-11:15am Be the Most Memorable Person in the International Center for Professional Room: Your Non-Verbal Advantage Development (ICPD) Speaker: Todd Fonseca, VP, Medtronic 8:15-10:15am SMDP Intro
    [Show full text]
  • Risperdal), Diabetes (Invokana), Psoriasis (Stelara), Migraines (Topamax), Heart Disease (Xarelto) and Attention Deficit Disorder (Concerta)
    CHAPTER 1 THE CREDO COMPANY By Steven Bril Letter From the Editors BACKSTAGE AT JOHNSON & JOHNSON On May 20, about 100 stock analysts gathered in the ballroom of the Hyatt Regency Hotel in New Brunswick, New Jersey, to hear good news from top executives at Johnson & Johnson: The company had 10 new drugs in the pipeline that might achieve more than a billion dollars in annual sales. For 129 years, New Brunswick has served as the headquarters of J&J, America’s seventh most valuable public company. With consumer products from Band-Aids to baby powder, Neutrogena to Rogaine, Listerine to Visine, Aveeno to Tylenol and Sudafed to Splenda, Johnson & Johnson is the biggest and, according to multiple surveys, most admired corporation in the world’s most prosperous industry—healthcare. But the real money—about 80 percent of its revenue and 91 percent of its profit—comes not from those consumer favorites, but from Johnson & Johnson’s high-margin medical devices: artificial hips and knees, heart stents, surgical tools and monitoring devices; and from still higher-margin prescription drugs targeting Crohn’s disease (Remicade), cancer (Zytiga, Velcade), schizophrenia (Risperdal), diabetes (Invokana), psoriasis (Stelara), migraines (Topamax), heart disease (Xarelto) and attention deficit disorder (Concerta). How J&J Makes Its Money Ads for many of these products dominate our television screens and magazine pages. Each drug relies on its own elaborate marketing plan and carefully pitched promotional materials, used by hundreds of salespeople whose incomes turn on how much product they can push to the thousands of doctors who write prescriptions. All command increasing portions of our health insurance premiums and our own wallets, as well as our hopes and anxiety when we or our loved ones fall ill.
    [Show full text]